Published in Arch Ophthalmol on September 01, 2012
Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol (2013) 1.01
Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol (2013) 0.91
Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res (2016) 0.85
Age-related macular degeneration and mortality in community-dwelling elders: the age, gene/environment susceptibility Reykjavik study. Ophthalmology (2014) 0.84
Complement polymorphisms and cognitive dysfunction after carotid endarterectomy. J Neurosurg (2013) 0.82
Misclassification can explain most apparent regression of age-related macular degeneration: results from multistate models with misclassification. Invest Ophthalmol Vis Sci (2014) 0.79
Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study. JAMA Ophthalmol (2015) 0.79
Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. Invest Ophthalmol Vis Sci (2016) 0.77
CFH Y402H polymorphism and the complement activation product C5a: effects on NF-κB activation and inflammasome gene regulation. Br J Ophthalmol (2016) 0.76
Risk characteristics of the combined geographic atrophy and choroidal neovascularisation phenotype in age-related macular degeneration. Br J Ophthalmol (2014) 0.76
Anaphylatoxins Activate Ca(2+), Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment Epithelium. Front Immunol (2017) 0.75
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 10.88
The Wisconsin age-related maculopathy grading system. Ophthalmology (1991) 7.62
The Beaver Dam Eye Study: visual acuity. Ophthalmology (1991) 6.87
The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology (1997) 6.47
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet (2005) 6.36
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology (2007) 3.96
Drusen and disciform macular detachment and degeneration. Arch Ophthalmol (1973) 3.87
Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology (2002) 3.80
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA (2007) 3.34
Changes in visual acuity in a population. The Beaver Dam Eye Study. Ophthalmology (1996) 2.98
Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci (2008) 2.91
Multi-state models for event history analysis. Stat Methods Med Res (2002) 2.80
Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol (2006) 2.77
Changes in visual acuity in a population over a 10-year period : The Beaver Dam Eye Study. Ophthalmology (2001) 2.71
The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol (2003) 2.63
The validity of self-reported and surrogate-reported cataract and age-related macular degeneration in the Beaver Dam Eye Study. Am J Epidemiol (1991) 2.14
Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci (2001) 2.04
Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol (2003) 2.04
Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol (2008) 1.98
Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology (2007) 1.86
Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Arch Ophthalmol (1995) 1.76
Risk assessment model for development of advanced age-related macular degeneration. Arch Ophthalmol (2011) 1.75
Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Stat Med (1994) 1.62
Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology (2011) 1.61
Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol (2004) 1.59
Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol (2006) 1.58
Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology (2002) 1.51
Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol (1998) 1.47
The validity of inferences based on incomplete observations in disease state models. Biometrics (1991) 1.31
Multi-state models and diabetic retinopathy. Stat Med (1995) 1.21
Inference for multi-state models from interval-censored data. Stat Methods Med Res (2002) 1.18
14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology (2005) 1.15
Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology (2003) 1.03
Seven year follow-up of age-related maculopathy in an elderly British population. Eye (Lond) (1997) 0.98
Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology (2005) 0.96
Age-related macular degeneration and mortality: the Beijing eye study. Ophthalmologica (2008) 0.78
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279. Graefes Arch Clin Exp Ophthalmol (2011) 0.77
Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Diabetic retinopathy. N Engl J Med (2012) 5.79
Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol (2006) 4.68
The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol (2004) 4.64
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA (2010) 4.41
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Retinopathy in diabetes. Diabetes Care (2004) 4.25
Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology (2007) 3.96
The impact of hearing loss on quality of life in older adults. Gerontologist (2003) 3.87
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology (2002) 3.80
Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol (2004) 3.78
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol (2005) 3.74
Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology (2004) 3.53
Revised formulas for summarizing retinal vessel diameters. Curr Eye Res (2003) 3.47
Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int (2012) 3.46
Prevalence of olfactory impairment in older adults. JAMA (2002) 3.46
Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet (2008) 3.42
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology (2008) 3.37
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology (2005) 3.28
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
The 5-year incidence and progression of hearing loss: the epidemiology of hearing loss study. Arch Otolaryngol Head Neck Surg (2003) 3.17
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
Diabetic retinopathy. Diabetes Care (2004) 2.97
Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology (2006) 2.95
Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet (2003) 2.92
The economic burden of major adult visual disorders in the United States. Arch Ophthalmol (2006) 2.92
The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol (2006) 2.89
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol (2011) 2.89
Retinal vascular caliber and the development of hypertension: a meta-analysis of individual participant data. J Hypertens (2014) 2.83
Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci (2006) 2.79
Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA (2002) 2.78
Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol (2006) 2.77
Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA (2002) 2.72
Long-term use of aspirin and age-related macular degeneration. JAMA (2012) 2.72
Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care (2002) 2.70
The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology (2004) 2.68
Detection of age-related macular degeneration using a nonmydriatic digital camera and a standard film fundus camera. Arch Ophthalmol (2004) 2.67
ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst (2002) 2.64
Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med (2006) 2.60
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology (2003) 2.49
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology (2007) 2.46
Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet (2013) 2.36
The prevalence and risk factors of retinal microvascular abnormalities in older persons: The Cardiovascular Health Study. Ophthalmology (2003) 2.36
Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet (2005) 2.34
Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology (2004) 2.26
Detecting disease-causing genes by LASSO-Patternsearch algorithm. BMC Proc (2007) 2.25
The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol (2008) 2.24
Generational differences in the prevalence of hearing impairment in older adults. Am J Epidemiol (2009) 2.18
Retinal arteriolar diameter and risk for hypertension. Ann Intern Med (2004) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology (2004) 2.12
Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ (2004) 2.10
Low birthweight is associated with narrower arterioles in adults. Hypertension (2008) 2.08
Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care (2009) 2.08